91 related articles for article (PubMed ID: 8338346)
1. Dopa resistance in multiple-system atrophy: loss of postsynaptic D2 receptors.
Churchyard A; Donnan GA; Hughes A; Howells DW; Woodhouse D; Wong JY; Kalnins RM; Mendelsohn FA; Paxinos G
Ann Neurol; 1993 Aug; 34(2):219-26. PubMed ID: 8338346
[TBL] [Abstract][Full Text] [Related]
2. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
Rioux L; Frohna PA; Joyce JN; Schneider JS
Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
[TBL] [Abstract][Full Text] [Related]
3. Dopamine D1 and D2 receptors in progressive supranuclear palsy: an autoradiographic study.
Pascual J; Berciano J; Grijalba B; del Olmo E; González AM; Figols J; Pazos A
Ann Neurol; 1992 Nov; 32(5):703-7. PubMed ID: 1449252
[TBL] [Abstract][Full Text] [Related]
4. Organization of dopamine D1 and D2 receptors in human striatum: receptor autoradiographic studies in Huntington's disease and schizophrenia.
Joyce JN; Lexow N; Bird E; Winokur A
Synapse; 1988; 2(5):546-57. PubMed ID: 2973147
[TBL] [Abstract][Full Text] [Related]
5. Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism.
St-Hilaire M; Landry E; Lévesque D; Rouillard C
Neurobiol Dis; 2005 Nov; 20(2):450-60. PubMed ID: 15896973
[TBL] [Abstract][Full Text] [Related]
6. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution.
Piggott MA; Marshall EF; Thomas N; Lloyd S; Court JA; Jaros E; Burn D; Johnson M; Perry RH; McKeith IG; Ballard C; Perry EK
Brain; 1999 Aug; 122 ( Pt 8)():1449-68. PubMed ID: 10430831
[TBL] [Abstract][Full Text] [Related]
7. Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation.
Darmopil S; Martín AB; De Diego IR; Ares S; Moratalla R
Biol Psychiatry; 2009 Sep; 66(6):603-13. PubMed ID: 19520364
[TBL] [Abstract][Full Text] [Related]
8. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine.
Morissette M; Goulet M; Calon F; Falardeau P; Blanchet PJ; Bédard PJ; Di Paolo T
Mol Pharmacol; 1996 Nov; 50(5):1073-9. PubMed ID: 8913337
[TBL] [Abstract][Full Text] [Related]
9. Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease.
Ryoo HL; Pierrotti D; Joyce JN
Mov Disord; 1998 Sep; 13(5):788-97. PubMed ID: 9756147
[TBL] [Abstract][Full Text] [Related]
10. Striatal dopaminergic terminals in type 1 and type 2 alcoholics measured with [3H]dihydrotetrabenazine and human whole hemisphere autoradiography.
Tupala E; Häkkinen M; Storvik M; Tiihonen J
Psychiatry Res; 2008 May; 163(1):70-5. PubMed ID: 18394867
[TBL] [Abstract][Full Text] [Related]
11. Phenotypical characterization of the neurons expressing the D1 and D2 dopamine receptors in the monkey striatum.
Aubert I; Ghorayeb I; Normand E; Bloch B
J Comp Neurol; 2000 Feb; 418(1):22-32. PubMed ID: 10701753
[TBL] [Abstract][Full Text] [Related]
12. Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease.
Weeks RA; Piccini P; Harding AE; Brooks DJ
Ann Neurol; 1996 Jul; 40(1):49-54. PubMed ID: 8687191
[TBL] [Abstract][Full Text] [Related]
13. In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias.
Turjanski N; Lees AJ; Brooks DJ
Neurology; 1997 Sep; 49(3):717-23. PubMed ID: 9305330
[TBL] [Abstract][Full Text] [Related]
14. Loss of synaptic D1 dopamine/N-methyl-D-aspartate glutamate receptor complexes in L-DOPA-induced dyskinesia in the rat.
Fiorentini C; Rizzetti MC; Busi C; Bontempi S; Collo G; Spano P; Missale C
Mol Pharmacol; 2006 Mar; 69(3):805-12. PubMed ID: 16365282
[TBL] [Abstract][Full Text] [Related]
15. What has been learnt from study of dopamine receptors in Parkinson's disease?
Hurley MJ; Jenner P
Pharmacol Ther; 2006 Sep; 111(3):715-28. PubMed ID: 16458973
[TBL] [Abstract][Full Text] [Related]
16. Abnormal dopamine uptake sites in postmortem striatum from patients with Tourette's syndrome.
Singer HS; Hahn IH; Moran TH
Ann Neurol; 1991 Oct; 30(4):558-62. PubMed ID: 1838678
[TBL] [Abstract][Full Text] [Related]
17. Differential expression of D1 and D2 dopamine and m4 muscarinic acetylcholine receptor proteins in identified striatonigral neurons.
Ince E; Ciliax BJ; Levey AI
Synapse; 1997 Dec; 27(4):357-66. PubMed ID: 9372558
[TBL] [Abstract][Full Text] [Related]
18. Failure of neuroprotection by embryonic striatal grafts in a double lesion rat model of striatonigral degeneration (multiple system atrophy).
Puschban Z; Waldner R; Seppi K; Stefanova N; Humpel C; Scherfler C; Levivier M; Poewe W; Wenning GK
Exp Neurol; 2000 Jul; 164(1):166-75. PubMed ID: 10877927
[TBL] [Abstract][Full Text] [Related]
19. Dopamine D2 receptor density remains constant in treated Parkinson's disease.
Guttman M; Seeman P; Reynolds GP; Riederer P; Jellinger K; Tourtellotte WW
Ann Neurol; 1986 May; 19(5):487-92. PubMed ID: 2940960
[TBL] [Abstract][Full Text] [Related]
20. Loss of dopamine D2 receptors in Alzheimer's disease with parkinsonism but not Parkinson's or Alzheimer's disease.
Joyce JN; Murray AM; Hurtig HI; Gottlieb GL; Trojanowski JQ
Neuropsychopharmacology; 1998 Dec; 19(6):472-80. PubMed ID: 9803423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
